244 related articles for article (PubMed ID: 36116415)
1. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract][Full Text] [Related]
2. Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping.
Xiao Y; Xu G; Cloyd JM; Du S; Mao Y; Pawlik TM
J Gastrointest Surg; 2022 Aug; 26(8):1670-1678. PubMed ID: 35508682
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
4. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
5. Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.
Liu L; Wang S; Cen C; Peng S; Chen Y; Li X; Diao N; Li Q; Ma L; Han P
Mol Med Rep; 2019 Aug; 20(2):1901-1914. PubMed ID: 31257501
[TBL] [Abstract][Full Text] [Related]
6. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
7. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
8. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.
Zheng B; Peng J; Mollayup A; Bakri A; Guo L; Zheng J; Xu H
Mol Med Rep; 2018 Jan; 17(1):216-224. PubMed ID: 29115420
[TBL] [Abstract][Full Text] [Related]
9. Identification of key regulators of pancreatic ductal adenocarcinoma using bioinformatics analysis of microarray data.
Li N; Zhao X; You S
Medicine (Baltimore); 2019 Jan; 98(2):e14074. PubMed ID: 30633213
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatic Analysis Suggests That Three Hub Genes May Be a Vital Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Chang X; Yang MF; Fan W; Wang LS; Yao J; Li ZS; Li DF
J Comput Biol; 2020 Nov; 27(11):1595-1609. PubMed ID: 32216644
[TBL] [Abstract][Full Text] [Related]
12. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma.
Fan L; Wang X; Chang Q; Wang Y; Yang W; Liu L
Medicine (Baltimore); 2022 Oct; 101(42):e30966. PubMed ID: 36281157
[TBL] [Abstract][Full Text] [Related]
13. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
14. Construction of a circRNA-miRNA-mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma.
Xiao Y
J Cell Biochem; 2020 Jan; 121(1):394-406. PubMed ID: 31232492
[TBL] [Abstract][Full Text] [Related]
15. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
[TBL] [Abstract][Full Text] [Related]
16. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
[TBL] [Abstract][Full Text] [Related]
17. PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression.
Almeida PP; Cardoso CP; de Freitas LM
BMC Cancer; 2020 Jan; 20(1):82. PubMed ID: 32005189
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
19. Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods.
Lu Y; Li C; Chen H; Zhong W
Mol Biol Rep; 2018 Dec; 45(6):1799-1807. PubMed ID: 30173393
[TBL] [Abstract][Full Text] [Related]
20. Identification of potential core genes at single-cell level contributing to pathogenesis of pancreatic ductal adenocarcinoma through bioinformatics analysis.
Du B; Su F; Wang H; Liang H; Song X; Shao Z; Wei Y
Cancer Biomark; 2022; 34(1):1-12. PubMed ID: 35068444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
